Growth factor priming differentially modulates components of the extracellular matrix proteome in chondrocytes and synovium-derived stem cells

PLoS One. 2014 Feb 7;9(2):e88053. doi: 10.1371/journal.pone.0088053. eCollection 2014.

Abstract

To make progress in cartilage repair it is essential to optimize protocols for two-dimensional cell expansion. Chondrocytes and SDSCs are promising cell sources for cartilage repair. We previously observed that priming with a specific growth factor cocktail (1 ng/mL transforming growth factor-β1, 5 ng/mL basic fibroblast growth factor, and 10 ng/mL platelet-derived growth factor-BB) in two-dimensional culture, led to significant improvement in mechanical and biochemical properties of synovium-derived stem cell (SDSC)-seeded constructs. The current study assessed the effect of growth factor priming on the proteome of canine chondrocytes and SDSCs. In particular, growth factor priming modulated the proteins associated with the extracellular matrix in two-dimensional cultures of chondrocytes and SDSCs, inducing a partial dedifferentiation of chondrocytes (most proteins associated with cartilage were down-regulated in primed chondrocytes) and a partial differentiation of SDSCs (some collagen-related proteins were up-regulated in primed SDSCs). However, when chondrocytes and SDSCs were grown in pellet culture, growth factor-primed cells maintained their chondrogenic potential with respect to glycosaminoglycan and collagen production. In conclusion, the strength of the label-free proteomics technique is that it allows for the determination of changes in components of the extracellular matrix proteome in chondrocytes and SDSCs in response to growth factor priming, which could help in future tissue engineering strategies.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Becaplermin
  • Cell Proliferation / drug effects
  • Chondrocytes / drug effects*
  • Chondrocytes / metabolism
  • Chondrogenesis / drug effects
  • Dogs
  • Extracellular Matrix / drug effects*
  • Extracellular Matrix / metabolism
  • Fibroblast Growth Factor 2 / pharmacology*
  • Proteome
  • Proto-Oncogene Proteins c-sis / pharmacology*
  • Stem Cells / drug effects*
  • Stem Cells / metabolism
  • Synovial Membrane / cytology
  • Synovial Membrane / drug effects*
  • Synovial Membrane / metabolism
  • Tissue Engineering / methods
  • Transforming Growth Factor beta1 / pharmacology*

Substances

  • Proteome
  • Proto-Oncogene Proteins c-sis
  • Transforming Growth Factor beta1
  • Fibroblast Growth Factor 2
  • Becaplermin